Generate a tailored SOP for Dr. Colin Pritchard. Improve your application with a focused, well-structured draft.
Colin C. Pritchard is a Professor and Co-Director of the Genetics Solid Tumors Laboratory at UW Medicine, also heading the Precision Diagnostics Platform at the Brotman Baty Institute for Precision Medicine. His research focuses on cancer molecular diagnostics, primarily developing innovative diagnostic methods to detect germline and somatic mutations that can guide therapeutic decision-making. His laboratory has pioneered assays like 'ColoSeq™' and 'UW-OncoPlex™', which are now clinically available and utilize advanced multiplexed sequencing techniques to detect mutations across hundreds of genes. Dr. Pritchard’s work extends to noninvasive sampling methods to capture cancer mutations from cell-free microRNA, cell-free DNA, and circulating tumor-associated nucleic acids. He investigates the biological variations affecting serum and plasma biomarkers, which play a critical role in the interpretation of liquid biopsy results. His involvement in prostate cancer research aims to transform precision medicine for men with prostate cancer, developing new diagnostics and identifying predictive biomarkers. Dr. Pritchard is also involved in enhancing the diagnosis of Lynch syndrome, a hereditary condition linked to various cancers, and has established methods for detecting microsatellite instability relevant to this condition.
Standard Graduate School requirements for University of Washington apply to most departments listed unless specified otherwise by the program.